SCOLR IND
This article was originally published in The Tan Sheet
Executive Summary
Bellevue, Wash.-based firm has submitted an investigational new drug application with FDA in advance of conducting studies on extended-release ibuprofen in humans, the firm announces. The trial is slated to begin in early 2005, with an NDA submission planned for the summer, SCOLR adds. The firm initially aimed to begin human trials in Canada this fall (1"The Tan Sheet" Aug. 2, 2004, p. 12)...
You may also be interested in...
Ibuprofen Extended-Release NDA Slated For 2005, SCOLR Pharma Says
SCOLR Pharma plans to file an NDA in summer 2005 for CDT extended-release 12-hour ibuprofen tablets, the firm announced July 26
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.